SFN exhibits anti-cancer activities by activation of caspase-3, inhibition of DNMT and HDAC activity, and by reduction in ERα levels [29–32]; these mechanisms of anticancer activity are different from the mechanism by which DOX kills cancer cells [3, 16, 17]. The gene discussed is ESR1; the disease is cancer.